MPV17-Related Mitochondrial DNA Maintenance Syndrome

Authors: Almannai, Mohammed; El-Hattab, Ayman W; Scaglia, Fernando; Craigen, William J

Abstract

CLINICAL CHARACTERISTICS: MPV17-related mitochondrial DNA (mtDNA) maintenance syndrome presents in most affected individuals as an early-onset encephalohepatopathic (hepatocerebral) disease that is typically associated with mtDNA depletion, particularly in the liver. A later-onset disease, MPV17-related Charcot-Marie-Tooth disease type 2 (CMT2EE), characterized by myopathy and neuropathy and associated with multiple mtDNA deletions in muscle, has also rarely been described. MPV17-related encephalohepatopathy is characterized by hepatic manifestations (liver dysfunction that typically progresses to liver failure, cholestasis, hepatomegaly, and steatosis); neurologic involvement (developmental delay, hypotonia, microcephaly, and motor and sensory peripheral neuropathy); gastrointestinal manifestations (faltering growth, gastrointestinal dysmotility, and feeding difficulties); and metabolic derangements (lactic acidosis and hypoglycemia). Less frequent manifestations include renal tubulopathy, nephrocalcinosis, and hypoparathyroidism. Progressive liver disease often leads to death in infancy or early childhood. Hepatocellular carcinoma has been reported. DIAGNOSIS/TESTING: The diagnosis of MPV17-related mtDNA maintenance syndrome is established in a proband with biallelic pathogenic variants in MPV17 identified by molecular genetic testing. MANAGEMENT: Treatment of manifestations: Ideally management is by a multidisciplinary team including specialists in hepatology, nutrition, gastroenterology, neurology, clinical genetics, and child development. Nutritional support should be provided by a dietitian experienced in managing children with liver diseases; prevention of hypoglycemia requires frequent feeds and uncooked cornstarch (1-2 g/kg/dose). Although liver transplantation remains the only treatment option for liver failure, it is controversial because of the multisystem involvement in this disorder. Surveillance: Liver function tests, liver ultrasound, liver elastography, and serum alpha-fetoprotein concentration as needed based on clinical severity to assess progression of liver disease; assess nutrition, neurologic findings, and development at each visit; brain MRI, nerve conduction velocity, and EEG as needed; measure serum glucose, urinalysis, urine amino acids, and ophthalmology examination with frequency depending on clinical severity. Agents/circumstances to avoid: Prolonged fasting; perinatal treatment with antiretroviral drug zidovudine for HIV prophylaxis accelerated onset and progression of MPV17-related encephalohepatopathy; medications that are toxic or potentially toxic to persons with Charcot-Marie-Tooth disease. GENETIC COUNSELING: MPV17-related mtDNA maintenance syndrome is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an MPV17 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the MPV17 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.